Literature DB >> 36219364

Diminished PD-L1 regulation along with dysregulated T lymphocyte subsets and chemokine in ANCA-associated vasculitis.

Jagdeep Singh1, Ranjana Walker Minz2, Biman Saikia1, Ritambhra Nada3, Aman Sharma4, Saket Jha4, Shashi Anand1, Manish Rathi5, Sanjay D'Cruz6.   

Abstract

ANCA-associated vasculitis (AAV) is a life-threatening disease characterized by small vessel inflammation and pathogenic self-directed antibodies. Programmed death-ligand 1 receptor (PD-1) and programmed cell death ligand-1 (PD-L1) are immune checkpoint molecules crucial for maintaining tolerance and immune homeostasis. After checkpoint inhibition therapy, development of various autoimmune diseases and immune-related adverse events (irAEs) have been observed. Here, we investigated the immunomodulatory roles of neutrophils through the expression of immune checkpoint molecule (PD-L1), migratory molecules (CXCR2), chemotactic chemokines (CXCL5) and other important molecules (BAFF and HMGB1) in development of AAV. We also scrutinized the immune mechanism responsible for development of pauci-immune crescentic GN (PICGN). We demonstrate for the first time that the frequency of PD-L1 expressing neutrophils was significantly reduced in AAV patients compared to healthy controls and correlated negatively with disease severity (BVASv3). Further, in renal biopsy, reduced PD-L1 immune checkpoint expression provides a microenvironment that unleashes uncontrolled activated CD4 + T cells, B cells, neutrophils and macrophages and ultimately causes engulfment of immune complexes leading to PICGN. Furthermore, during remission, reduced neutrophils PD-L1 and CXCR2 expression, increased neutrophils CXCL5 expression and increased peripheral effector memory T cells and increased HMGB1 and BAFF levels in serum, demonstrate the propensity for the persistence of sub-clinical inflammation, which could explain relapse, in this group of diseases.
© 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Entities:  

Keywords:  ANCA-associated vasculitis; Pauci-immune crescentic glomerulonephritis; Programmed death-ligand 1; Sub-clinical inflammation

Year:  2022        PMID: 36219364     DOI: 10.1007/s10238-022-00908-y

Source DB:  PubMed          Journal:  Clin Exp Med        ISSN: 1591-8890            Impact factor:   5.057


  41 in total

Review 1.  ANCA disease: where is this field heading?

Authors:  Ronald J Falk; J Charles Jennette
Journal:  J Am Soc Nephrol       Date:  2010-04-15       Impact factor: 10.121

2.  T-Lymphocyte Infiltration to Islets in the Pancreas of a Patient Who Developed Type 1 Diabetes After Administration of Immune Checkpoint Inhibitors.

Authors:  Sho Yoneda; Akihisa Imagawa; Yoshiya Hosokawa; Megu Yamaguchi Baden; Takekazu Kimura; Sae Uno; Kenji Fukui; Kunihito Goto; Motohide Uemura; Hidetoshi Eguchi; Hiromi Iwahashi; Junji Kozawa; Iichiro Shimomura
Journal:  Diabetes Care       Date:  2019-05-10       Impact factor: 19.112

3.  Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) induced by immune checkpoint inhibitors.

Authors:  Anissa Roger; Matthieu Groh; Gwenael Lorillon; Claire Le Pendu; Jeremy Maillet; Dimitri Arangalage; Abdellatif Tazi; Celeste Lebbe; Barouyr Baroudjian; Julie Delyon
Journal:  Ann Rheum Dis       Date:  2018-06-23       Impact factor: 19.103

4.  Rapid granulomatosis with polyangiitis induced by immune checkpoint inhibition.

Authors:  Rob R H van den Brom; Wayel H Abdulahad; Abraham Rutgers; Bart-Jan Kroesen; Caroline Roozendaal; Derk Jan A de Groot; Carolien P Schröder; Geke A P Hospers; Elisabeth Brouwer
Journal:  Rheumatology (Oxford)       Date:  2016-04-11       Impact factor: 7.580

5.  Renal Vasculitis and Pauci-immune Glomerulonephritis Associated With Immune Checkpoint Inhibitors.

Authors:  Alexander J Gallan; Ellen Alexander; Pankti Reid; Fouad Kutuby; Anthony Chang; Kammi J Henriksen
Journal:  Am J Kidney Dis       Date:  2019-06-14       Impact factor: 8.860

6.  2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides.

Authors:  J C Jennette; R J Falk; P A Bacon; N Basu; M C Cid; F Ferrario; L F Flores-Suarez; W L Gross; L Guillevin; E C Hagen; G S Hoffman; D R Jayne; C G M Kallenberg; P Lamprecht; C A Langford; R A Luqmani; A D Mahr; E L Matteson; P A Merkel; S Ozen; C D Pusey; N Rasmussen; A J Rees; D G I Scott; U Specks; J H Stone; K Takahashi; R A Watts
Journal:  Arthritis Rheum       Date:  2013-01

7.  PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity.

Authors:  Vikram R Juneja; Kathleen A McGuire; Robert T Manguso; Martin W LaFleur; Natalie Collins; W Nicholas Haining; Gordon J Freeman; Arlene H Sharpe
Journal:  J Exp Med       Date:  2017-03-16       Impact factor: 14.307

8.  Granulomatosis With Polyangiitis in a Patient on Programmed Death-1 Inhibitor for Advanced Non-small-cell Lung Cancer.

Authors:  Anne Sibille; Romain Alfieri; Olivier Malaise; Nancy Detrembleur; Michelle Pirotte; Renaud Louis; Bernard Duysinx
Journal:  Front Oncol       Date:  2019-06-06       Impact factor: 6.244

Review 9.  The Diverse Function of PD-1/PD-L Pathway Beyond Cancer.

Authors:  Weiting Qin; Lipeng Hu; Xueli Zhang; Shuheng Jiang; Jun Li; Zhigang Zhang; Xu Wang
Journal:  Front Immunol       Date:  2019-10-04       Impact factor: 7.561

Review 10.  Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors.

Authors:  Angeliki M Stamatouli; Zoe Quandt; Ana Luisa Perdigoto; Pamela L Clark; Harriet Kluger; Sarah A Weiss; Scott Gettinger; Mario Sznol; Arabella Young; Robert Rushakoff; James Lee; Jeffrey A Bluestone; Mark Anderson; Kevan C Herold
Journal:  Diabetes       Date:  2018-06-24       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.